- Welcome and Introduction
- Overview of CAR T-Cell Therapy
- Clinical Data on Approved CAR T-cell Therapies in Multiple Myeloma
- CAR T-cell Therapies in Development for Multiple Myeloma
- Panel Discussion
- Audience Question and Answer Session
Jesús G. Berdeja, MD
Director of Multiple Myeloma Research
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancer
Sagar Lonial, MD
Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
The goal of this program is to improve the knowledge and competence of learners in integrating CAR T-cell therapy into treatment plans for patients with hematologic malignancies.
This educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with hematologic malignancies who are eligible for CAR T-cell therapy.
Upon completion of this activity, participants should be able to:
- Discover the similarities and differences among currently available and emerging CAR T-cell therapies in multiple myeloma
- Identify patients who are likely to benefit from CAR T-cell therapy or are eligible for clinical trial enrollment
- Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of multiple myeloma
- Manage toxicities associated with CAR T-cell therapy using available guidelines and online clinical resources and tools, and implement strategies to educate patients eligible for this treatment about the potential for these complications
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.